【中文摘要】 目的：探讨晚期非小细胞肺癌患者(NSCLC)机体DNA修复能力(DNA repair capacity，DRC)与顺铂为基础方案化疗后产生耐药之间的关系，为临床预测晚期非小细胞肺癌患者对顺铂方案化疗是否有效提供理论依据。 方法：取经病理确诊的96例不可切除晚期非小细胞肺癌患者外周血，提取和培养淋巴细胞，进行宿主细胞反应(Host cell reaction，HCR)实验，计算DRC值以检测患者机体DNA修复能力。同时患者均接受以顺铂(Cisplatin，DDP)为基础的方案化疗，至少2个周期，观察并比较不同DRC值的患者对顺铂化疗疗效以及化疗后生存的差异。 结果：1)96例患者的DRC值为7.5％±1.1％。DRC≤6.7％组的化疗有效率(RR=CR+PR)为42.86％，失败风险(SD+PD)57.14％。6.7％＜DRC＜8.9％组化疗有效率39.39％，与DRC≤6.7％组42.86％的化疗有效率相比较，X~2值为0.075，P=0.784，无统计学差异；6.7％＜DRC＜8.9％组的化疗失败风险为60.60％，与DRC≤6.7％组57.14％的失败风险相比较，比值比OR...

【英文摘要】 OBJECTIVE To approach The Correlation of DNA repair capacity and cisplatin resistance in Advanced Non-Small-Cell Lung Cancer, and to provide theoretical supports for predicting the efficacy of cisplatin-based chemotherapy on Non-small-cell lung cancer patients. METHOD To measure the DNA repair capacity by the host cell reaction (HCR) assay by lymphocytes extracted from the peripheral blood of 96 cases of Non-small-cell lung cancer patients who was final diagnosed by pathology and could not take surgery. ...